WO2012103015A3 - Patchs transdermiques à libération prolongée associant un bêta-agoniste et un stéroïde et leurs procédés d'utilisation - Google Patents

Patchs transdermiques à libération prolongée associant un bêta-agoniste et un stéroïde et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2012103015A3
WO2012103015A3 PCT/US2012/022232 US2012022232W WO2012103015A3 WO 2012103015 A3 WO2012103015 A3 WO 2012103015A3 US 2012022232 W US2012022232 W US 2012022232W WO 2012103015 A3 WO2012103015 A3 WO 2012103015A3
Authority
WO
WIPO (PCT)
Prior art keywords
transdermal patches
steroid
extended
beta agonist
methods
Prior art date
Application number
PCT/US2012/022232
Other languages
English (en)
Other versions
WO2012103015A2 (fr
Inventor
Larry J. Caldwell
Sadanobu Shirai
Original Assignee
Csi Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csi Gmbh filed Critical Csi Gmbh
Publication of WO2012103015A2 publication Critical patent/WO2012103015A2/fr
Publication of WO2012103015A3 publication Critical patent/WO2012103015A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des patchs transdermiques à libération prolongée associant un bêta-agoniste et un stéroïde. Les patchs transdermiques des modes de réalisation de l'invention présentent une matrice adhésive qui contient à la fois un bêta-agoniste, par exemple du tulobutérol, et un stéroïde, par exemple de la dexaméthasone, ladite matrice étant conçue pour être stable au stockage et assurer une libération prolongée du bêta-agoniste et du stéroïde. D'autres aspects de l'invention concernent des procédés d'utilisation desdits patchs transdermiques, par exemple pour le traitement d'affections pulmonaires, telles que l'asthme.
PCT/US2012/022232 2011-01-27 2012-01-23 Patchs transdermiques à libération prolongée associant un bêta-agoniste et un stéroïde et leurs procédés d'utilisation WO2012103015A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161436900P 2011-01-27 2011-01-27
US61/436,900 2011-01-27

Publications (2)

Publication Number Publication Date
WO2012103015A2 WO2012103015A2 (fr) 2012-08-02
WO2012103015A3 true WO2012103015A3 (fr) 2012-09-20

Family

ID=46581345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/022232 WO2012103015A2 (fr) 2011-01-27 2012-01-23 Patchs transdermiques à libération prolongée associant un bêta-agoniste et un stéroïde et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2012103015A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110433146B (zh) * 2018-05-03 2022-03-15 中国医学科学院药物研究所 一种妥洛特罗晶体贮库型透皮贴剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0439180A2 (fr) * 1990-01-26 1991-07-31 LTS LOHMANN THERAPIE-SYSTEME GmbH & CO.KG Système thérapeutique transdermique pour l'agent actif tulobuterol
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
US6117447A (en) * 1997-12-12 2000-09-12 Nitto Denko-Corporation Percutaneous absorption type preparation
WO2005046600A2 (fr) * 2003-11-07 2005-05-26 Nexmed Holdings, Inc. Systeme d'application de tulobuterol transdermique, procede et composition correspondants
US20050220852A1 (en) * 2003-06-20 2005-10-06 Teikoku Seiyaku Co., Ltd Adhesive patch containing tulobuterol
US20100158990A1 (en) * 2006-12-27 2010-06-24 Abielle Pharmaceuticals, Inc Transdermal method and patch for corticosteroid administration

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0439180A2 (fr) * 1990-01-26 1991-07-31 LTS LOHMANN THERAPIE-SYSTEME GmbH & CO.KG Système thérapeutique transdermique pour l'agent actif tulobuterol
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
US6117447A (en) * 1997-12-12 2000-09-12 Nitto Denko-Corporation Percutaneous absorption type preparation
US20050220852A1 (en) * 2003-06-20 2005-10-06 Teikoku Seiyaku Co., Ltd Adhesive patch containing tulobuterol
WO2005046600A2 (fr) * 2003-11-07 2005-05-26 Nexmed Holdings, Inc. Systeme d'application de tulobuterol transdermique, procede et composition correspondants
US20100158990A1 (en) * 2006-12-27 2010-06-24 Abielle Pharmaceuticals, Inc Transdermal method and patch for corticosteroid administration

Also Published As

Publication number Publication date
WO2012103015A2 (fr) 2012-08-02

Similar Documents

Publication Publication Date Title
IL278396A (en) Neuroactive steroids converted at the 19th position to the 17th position, their prodrugs, and methods of treatment using them
EP2533799B8 (fr) Procédé pour l'utilisation de progestogène comme sensibilisateur aux glucocorticoïdes
PH12015500545A1 (en) Methods for modulating corticosterone levels in psychologically stressed individuals
HK1200173A1 (en) Neuroactive steroids, compositions, and uses thereof
IL222695A0 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
WO2010054158A3 (fr) Modulateurs stéroïdiens du récepteur des glucocorticoïdes
EP2506913A4 (fr) Dispositifs, procédés et ensembles de délivrance de produits thérapeutiques à un pancréas
KR101881965B1 (ko) 스테롤 및/또는 그의 유도체를 포함하는 내오염성 조성물
EP3517105B8 (fr) Compositions adhésives transdermiques, dispositifs et procédés
AU2018256561A1 (en) Aminosteroids for the treatment of a PTP1B associated disease
EP3064562A4 (fr) Feuille de protection de surface et composition d'agent adhésif dispersé dans de l'eau pour feuille de protection de surface
WO2012129429A3 (fr) Compositions transdermiques comprenant une couche d'agent actif et une couche de conversion d'agent actif
WO2014188353A3 (fr) Procédés de préparation de déshydroépiandrostérone et de ses intermédiaires
EP2898879A4 (fr) Support pour timbre transdermique collant ou produit pharmaceutique collant, et timbre transdermique collant ainsi que produit pharmaceutique collant mettant en uvre celui-ci
WO2012103015A3 (fr) Patchs transdermiques à libération prolongée associant un bêta-agoniste et un stéroïde et leurs procédés d'utilisation
WO2012103016A3 (fr) Patchs transdermiques à libération prolongée associant un bêta-agoniste et un anticholinergique et leurs procédés d'utilisation
AU2013204801A1 (en) Composition and method for management of diabetes or pre-diabetes
EP2601944A4 (fr) Timbre transcutané et procédé permettant d'augmenter son adhérence
WO2013112806A3 (fr) Administration d'hormones par voie transdermique
EP2681287A4 (fr) Pièce adhésive et procédé d'utilisation de celui-ci
EP2755990B8 (fr) Procédé de préparation d'acide bétulinique
EP2767544A4 (fr) Substance amorphe de 17 -acétoxy-11 -(4-n,n-diméthylaminophényl)-19-norprégna-4,9-diène-3,20-dione et procédé de préparation de celle-ci
PL393255A1 (pl) Nowa fosfolipidowa pochodna betuliny i sposób jej otrzymywania
PL395902A1 (pl) Proces nakladania substancji klejacej na elementy stolarki budowlanej i rama wykonana z tych elementów
HK1186968A1 (en) Low-dose transdermal patches with high drug release

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12739014

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 04.10.2013)

122 Ep: pct application non-entry in european phase

Ref document number: 12739014

Country of ref document: EP

Kind code of ref document: A2